# A New Mutational and Epigenetic Signature to Predict Early OPSCC Relapse

> **NCT06138483** · — · UNKNOWN · sponsor: **Centro di Riferimento Oncologico - Aviano** · enrollment: 267 (estimated)

## Conditions studied

- Oropharyngeal Squamous Cell Carcinoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06138483
- **Lead sponsor:** Centro di Riferimento Oncologico - Aviano
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-19
- **Primary completion:** 2024-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 267 (ESTIMATED)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06138483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06138483, "A New Mutational and Epigenetic Signature to Predict Early OPSCC Relapse". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06138483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*